Аннотация
Представлен анализ отдаленных результатов лечения 88 первичных больных аденокарциномой толстой кишки в различных стадиях опухолевого процесса с учетом критериев системы TNM, сывороточных уровней маркеров ИФР-1, ИФР-2, ИФРСБ-1, ИФРСБ-2, ИФРСБ-3, VEGF, ММП-7. В качестве критерия прогноза использовали показатель общей выживаемости, оцененный методом Каплана-Майера, а также регрессионную многофакторную модель Кокса. Установили, что сывороточные маркеры ИФР-1, ИФРСБ-2 и VEGF наряду со стадией заболевания можно считать статистически значимыми независимыми факторами прогноза общей выживаемости больных колоректальным раком.
Список литературы
Заридзе Д.Г., Каприн А.Д., Стилиди И.С. Динамика заболеваемости и смертности от злокачественных новообразований в России. Вопросы онкологии. 2018; 64(5): 578-90
Moons L., Mariman A., Vermeir P., Colemont L., Clays E., Van Vlierberghe H., Vogelaers D. Sociodemographic factors and strategies in colorectal cancer screening: a narrative review and practical recommendations. Acta Clin. Belg. 2020; 75(1): 33-41.
Yakar S., Leroith D., Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. Cytokine Growth Factor Rev. 2005; 16(4-5): 407-20.
Conn G., Soderman D.D., Schaeffer M.-T., Wile M., Hatcher V.B., Thomas K.A. Purification of a glicoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. Proc. Natl. Acad. Sci. USA. 1990; 87(4): 1323-27.
van Beijnum J.R., Pieters W., Nowak-Sliwinska P., Griffioen A.W. Insulin-like growth factor axis targeting in cancer and tumour angiogenesis — the missing link. Biol. Rev. Camb. Philos. Soc. 2017; 92(3): 1755-68.
Folkman J. Tumor angiogenesis. Adv. Cancer Res. 1985; 43: 175-230.
Spannuth W.A., Nick A.M., Jennings N.B., Armaiz-Pena G.N., Mangala L.S., Danes C.G. et al. Functional significance of VEGFR-2 on ovarian cancer cells. Int. J. Cancer. 2009; 124(5): 1045-53.
Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646-74.
Duffy M.J., McGowan P.M., Gallagher W.M. Cancer invasion and metastasis: changing views. J. Pathol. 2008; 214(3): 283-93.
Kushlinskii N.E., Gershtein E.S., Nikolaev A.A., Delektorskaya V.V., Korotkova E.A., Dvorova E.K., Kostyleva O.I. Insulin-like growth factors (IGF), IGF-binding proteins (IGFBP), and vascular endothelial growth factor (VEGF) in blood serum of patients with colorectal cancer. Bull. Exp. Biol. Med. 2014; 156(5): 684-8.
Weiss J.M., Huang W.Y., Rinaldi S., Fears T.R., Chatterjee N., Chia D. et al. IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int. J. Cancer. 2007; 121(10): 2267-73.
Douglas J.B., Silverman D.T., Pollack M.N., Tao Y., Soliman A.S., Stolzenberg-Solomon R.Z. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 Molar Ratio and Risk of Pancreatic Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Epidemiol. Biomarkers Prev. 2010; 19(9): 2298-2306.
Harrison S., Lennon R., Holly J., Higgins J.P.T., Gardner M., Perks C. et al. Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis. Cancer Causes Control. 2017; 28(6): 497-528.
Gong Y., Zhang B., Liao Y., Tang Y., Mai C., Chen T., Tang H. Serum Insulin-Like Growth Factor Axis and the Risk of Pancreatic Cancer: Systematic Review and Meta-Analysis. Nutrients. 2017; 9(4): 394.
Zhi X., Lamperska K., Golusinski P., Schork N.J., Luczewski L., Golusinski W., Masternak M.M. Expression levels of insulin-like growth factors 1 and 2 in head and neck squamous cell carcinoma. Growth Horm. IGF Res. 2014; 24(4): 137-41.
Kalledsøe L., Dragsted L.O., Hansen L., Kyrø C., Grønbæk H., Tjønneland A., Olsen A. The insulin-like growth factor family and breast cancer prognosis: A prospective cohort study among postmenopausal women in Denmark. Growth Horm. IGF Res. 2019; 44: 33-42.
Altieri B., Colao A., Faggiano A. The role of insulin-like growth factor system in the adrenocortical tumors. Minerva Endocrinol. 2019; 44(1): 43-57.
Abdel-Rahman O. Insulin-like growth factor pathway aberrations and gastric cancer; evaluation of prognostic significance and assessment of therapeutic potentials. Med. Oncol. 2015; 32(1): 431.
Simons C.C., Schouten L.J., Godschalk R.W., van Engeland M., van den Brandt P.A., van Schooten F.J., Weijenberg M.P. Genetic Variants in the Insulin-like Growth Factor Pathway and Colorectal Cancer Risk in the Netherlands Cohort Study. Sci Rep. 2015; 5: 14126.
Kuemmerle J.F. Insulin-like growth factors in the gastrointestinal tract and liver. Endocrinol. Metab. Clin. North Am. 2012; 41(2): 409-23.
Gershtein E.S., Isaeva E.R., Kushlinsky D.N., Korotkova E.A., Ermilova V.D., Laktionov K.P., Adamyan L.V. Insulin-Like Growth Factors (IGF) and IGF-Binding Proteins (IGFBP) in the Serum of Patients with Ovarian Tumors. Bull. Exp. Biol. Med. 2016; 160(6): 814-6.
Majchrzak-Baczmańska D., Malinowski A. Does IGF-1 play a role in the biology of endometrial cancer? Ginekol. Pol. 2016; 87(8): 598-604.